Elsevier

The Lancet

Volume 336, Issue 8711, 11 August 1990, Pages 355-357
The Lancet

CLINICAL PRACTICE
Histamine-2-receptor antagonists and gastric cancer risk

https://doi.org/10.1016/0140-6736(90)91888-HGet rights and content

Abstract

The relation between use of histamine-2-receptor (H2-receptor) antagonists and gastric cancer risk was investigated in a case-control study in northern Italy. 563 patients with newly diagnosed, histologically confirmed gastric cancer were compared with 1501 controls who did not have neoplastic or gastrointestinal disorders. 36 (6·3%) cases and 59 (3·3%) controls had used H2-receptor antagonists (cimetidine or ranitidine). The relative risk (RR) for ever-use was 1·8 (95% confidence intervals [Cl] 1·2, 2·7). The increased risk was restricted to patients who had started treatment with H2-receptor antagonists within 5 years of the diagnosis of stomach cancer (RR 3·1; 95% Cl 1·8, 5·3). For first use of H2-receptor antagonists 5-9 years previously the RR was 1·5 (95% Cl 0·7, 3·3), and for first use 10 or more years previously RR was 0·2 (95% Cl 0·03, 0·8). Although the incidence of gastric cancer was raised for the first few years after the start of treatment with H2-receptor antagonists, this may reflect misdiagnosis of some early gastric cancers. The findings are against long-term persistence of an excess risk of gastric cancer in association with use of H2-receptor antagonists.

References (19)

There are more references available in the full text version of this article.

Cited by (41)

  • The end of diagnosis: When to stop testing

    2002, American Journal of Gastroenterology
    Citation Excerpt :

    Considering its common occurrence and benign nature, empirical therapy of functional upper GI appeared a cost-effective strategy, especially in young patients (6). When gastric cancer was still relatively common differential diagnosis of gastric ulcer, however, concerns were raised that in the occasional patient, antisecretory therapy would delay the diagnosis of cancer (7). A physician needs to be rather sure about a diagnosis for which therapy entails severe side effects and potential complications.

  • Revisiting the Efficacy and Safety of Ranitidine

    2021, Journal of the Indian Medical Association
View all citing articles on Scopus
View full text